Literature DB >> 24726097

Tracking Lung Clearance Index and chest CT in mild cystic fibrosis lung disease over a period of three years.

Susanne I Fuchs1, Monika Gappa2, Johannes Eder3, Karin M Unsinn4, Gratiana Steinkamp3, Helmut Ellemunter3.   

Abstract

INTRODUCTION: Lung disease remains the main cause of morbidity and mortality in patients with Cystic Fibrosis (CF). To detect lung disease before clinical symptoms become apparent, sensitive tools are essential. Spirometry is used for monitoring, but the FEV1 remains frequently normal throughout childhood. The Lung Clearance Index (LCI) calculated from Multiple Breath Washout (MBW) was introduced at the CF centre Innsbruck in 2007 for assessing ventilation inhomogeneity in patients with mild lung disease. We hypothesized that LCIs in 2007 are of prognostic value for the presence or absence of structural lung changes in later years.
METHODS: Between 2007 and 2010 MBW, spirometry and ultra-low-dose HR-CT were prospectively tracked in 36 patients (6-53 years) with a mean FEV1 ≥ 80% predicted in 2007.
RESULTS: At study start the majority of patients had abnormal CT scores and LCI results. While CT and spirometry remained largely stable throughout the study, LCI results slightly improved but still correlated with CT scores in 2010. LCI results in 2007 correlated with CT scores in 2010 while FEV1 did not. In 86% the LCI value in 2007 was indicative for the presence or absence of structural lung changes in 2010.
CONCLUSION: The LCI is a sensitive tool for detecting and tracking pulmonary changes. Extended structural changes are unlikely if the LCI is normal. The LCI has the potential to be used for monitoring the progression of early CF lung disease and assessing the effect of treatment in both clinical care and research settings.
Copyright © 2014 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Bhalla-score; Lung Clearance Index; Mild Cystic Fibrosis lung disease; Multiple Breath Washout; Ultra-low-dose chest computed tomography

Mesh:

Year:  2014        PMID: 24726097     DOI: 10.1016/j.rmed.2014.03.011

Source DB:  PubMed          Journal:  Respir Med        ISSN: 0954-6111            Impact factor:   3.415


  9 in total

1.  Forced oscillations and respiratory system modeling in adults with cystic fibrosis.

Authors:  Adma N Lima; Alvaro C D Faria; Agnaldo J Lopes; José M Jansen; Pedro L Melo
Journal:  Biomed Eng Online       Date:  2015-02-13       Impact factor: 2.819

2.  Pulmonary exacerbations and clinical outcomes in a longitudinal cohort of infants and preschool children with cystic fibrosis.

Authors:  Jordana E Hoppe; Brandie D Wagner; Scott D Sagel; Frank J Accurso; Edith T Zemanick
Journal:  BMC Pulm Med       Date:  2017-12-11       Impact factor: 3.317

3.  Differences in lung clearance index and functional residual capacity between two commercial multiple-breath nitrogen washout devices in healthy children and adults.

Authors:  Annelies M Zwitserloot; Evelyne J van den Born; Lena H A Raaijmakers; Wouter E Stalman; Marjanne van Smaalen; Maarten van den Berge; Monika Gappa; Gerard H Koppelman; Brigitte W M Willemse
Journal:  ERJ Open Res       Date:  2020-06-29

4.  Does Pseudomonas aeruginosa Colonization Affect Exercise Capacity in CF?

Authors:  Asterios Kampouras; Elpis Hatziagorou; Vasiliki Avramidou; Vasiliki Georgopoulou; Fotios Kirvassilis; John Tsanakas
Journal:  Pulm Med       Date:  2019-12-09

5.  4-week daily airway clearance using oscillating positive-end expiratory pressure versus autogenic drainage in bronchiectasis patients: a randomised controlled trial.

Authors:  Galit Livnat; Naama Yaari; Nili Stein; Lea Bentur; Moneera Hanna; Maya Harel; Yochai Adir; Michal Shteinberg
Journal:  ERJ Open Res       Date:  2021-11-08

6.  Personalized medicine with drugs targeting the underlying protein defect in cystic fibrosis: is monitoring of treatment response necessary?

Authors:  Katharina Niedermayr; Verena Gasser; Claudia Rueckes-Nilges; Dorothea Appelt; Johannes Eder; Teresa Fuchs; Lutz Naehrlich; Helmut Ellemunter
Journal:  Ther Adv Chronic Dis       Date:  2022-08-05       Impact factor: 4.970

7.  Maximal mid-expiratory flow is a surrogate marker of lung clearance index for assessment of adults with bronchiectasis.

Authors:  Wei-Jie Guan; Jing-Jing Yuan; Yong-Hua Gao; Hui-Min Li; Jin-Ping Zheng; Rong-Chang Chen; Nan-Shan Zhong
Journal:  Sci Rep       Date:  2016-06-24       Impact factor: 4.379

Review 8.  The EGFR-ADAM17 Axis in Chronic Obstructive Pulmonary Disease and Cystic Fibrosis Lung Pathology.

Authors:  Marta Stolarczyk; Bob J Scholte
Journal:  Mediators Inflamm       Date:  2018-01-09       Impact factor: 4.711

9.  Ivacaftor in People with Cystic Fibrosis and a 3849+10kb CT or D1152H Residual Function Mutation.

Authors:  Eitan Kerem; Malena Cohen-Cymberknoh; Reuven Tsabari; Michael Wilschanski; Joel Reiter; David Shoseyov; Alex Gileles-Hillel; Thea Pugatsch; Jane C Davies; Christopher Short; Clare Saunders; Cynthia DeSouza; James C Sullivan; Jamie R Doyle; Keval Chandarana; Nils Kinnman
Journal:  Ann Am Thorac Soc       Date:  2021-03
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.